Why no approved MOTS-c dosage exists
That is not evasion. It is the actual state of the record, and the rest of this explains why, what the circulating numbers really are, and what a buyer loses by working without a label.
A dose becomes official through a specific process. Human trials test different amounts in a defined population, measure what happens, and produce a range that balances effect against harm. A regulator reviews that work, and if it holds up, an approved amount appears on a label alongside the indication and the population it applies to.
This compound has not been through that process. It holds no marketing authorisation in any jurisdiction and is sold as a research chemical, which is a supply category rather than a medical one. There is no leaflet, because there is no approval that would require one to exist.
A dose is four things at once
A number on its own is not a dose. It is the least informative part of one.
Every row has to be filled for the top row to mean anything. A number without a verified concentration is arithmetic with an unknown in it. A number without an indication is an answer to a question nobody has stated.
| Part of a real dose | What it specifies | Where it comes from when it is real | Status here |
|---|---|---|---|
| Amount | How much substance | Human trials across a tested range | Not established in humans |
| Concentration | How much is in the volume you handle | A verified, licensed product | Depends entirely on the supplier |
| Interval and duration | How often and for how long | Pharmacokinetic and outcome data in humans | Not published |
| Population and indication | Who it is for and what for | A regulator approving a defined use | No approved indication anywhere |
Where the circulating numbers came from
Trace any confident figure back and it usually terminates in one of three places.
Animal work. The published efficacy literature is mouse and cell culture work on metabolic outcomes and metabolic signalling. Amounts used in mouse experiments do not convert to human amounts by body weight, and researchers do not treat them as if they do. Species differ in how they absorb, distribute and clear a substance, which is exactly what the early phase of human research is built to measure.
Forum consensus. A number appears, gets repeated, and after enough repetitions acquires the tone of a standard. Nothing was added along the way except confidence.
Seller convention. Vials are filled at a convenient strength, and the strength then implies a use. That is a manufacturing decision working backwards into a recommendation.
None of those is a bad-faith act on its own. The problem is what happens to a number when the reason it exists is stripped away and only the digits are passed on.
What a consultation does change
Some of it is genuinely valuable and worth paying for. A clinician can identify conditions that make the whole idea inadvisable, order baseline bloodwork so a later change means something, notice an interaction with existing medication, and take professional responsibility for the encounter. Those are real services.
What no consultation can do is create a dose that human research has not produced. The clinician has no private dataset. The gap between what is known and what you are asking is not a gap in their knowledge, it is a gap in the field, and money cannot cross it.
This is where a professional setting can lend a number authority it has not earned. A consulting room, a printed plan and a qualification all signal that the figure came from somewhere established. Ask where, and be willing to hear an honest answer, which would be that it is an estimate.
The protections that leave with the label
A label is not paperwork. Without one, several protections quietly disappear at once.
You lose verified identity and strength, so any calculation rests on a supplier's word. You lose an approved indication, so nobody has agreed what the substance is even for. You lose the known adverse effect list, because that list is built from human data that does not exist here. You lose the recall route that finds you when a batch is wrong, and the reporting system that spots a pattern of harm across many people before it reaches you.
You also lose the party who carries liability. In a licensed supply chain a manufacturer is answerable for what is in the container. Outside it, the person holding the risk is the person holding the vial.
The comparison the question usually skips
Somebody searching for an amount has already decided the compound is worth using and is now working out how. That order of operations is worth interrupting, because the interesting comparison is not between a smaller amount and a larger one.
The metabolic problem most buyers have in mind is one the regulated market already addresses. For blood glucose regulation and the conditions around it, there are licensed medicines whose amounts were established in human trials, whose labels state who they are for, and whose harms are listed because they were collected systematically. There are also non-drug approaches whose effects have been measured against comparison groups in humans rather than inferred from mice.
None of that means the licensed options suit everyone or that people are wrong to look further. It means the honest framing of the choice is not this compound against doing nothing. It is this compound, at an amount nobody can source, against an option where every part of the dose has already been specified by somebody who had to prove it.
Put that way, the missing number stops being a gap to fill from a forum and becomes a piece of information about where this sits. A substance with no established amount, no approved indication and no published human results is not a slightly less documented version of a treatment. It is at an earlier point in the process, and the price of being early is carried by whoever uses it first.
The one route to an actual number
There is no registered human trial of MOTS-c to wait for. The entry that circulates as one, NCT07505745, was filed by Hudson Biotech, whose name is on seven further records covering other peptides sold in this market, one of them self-described in its own summary as a fictional example. Reading the lead sponsor field takes about ten seconds, and it is the whole check.
The route to a defensible amount is unchanged, and nobody is currently walking it. Human trials would have to test a range in a defined population, measure what happened, and answer to somebody with the power to refuse. Until that work is funded and done, every number you meet is an estimate with a confident voice, and the confidence is the part that is manufactured.